Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.

导出 LinkOut

翻译打印收藏纠错

作者： Raymund R,Razonable ^[1] ; Sidna M,Tulledge-Scheitel ^[2] ; Sara N,Hanson ^[3] ; Richard F,Arndt ^[4] ; Leigh L,Speicher ^[5] ; Teresa A,Seville ^[6] ; Jennifer J,Larsen ^[7] ; Ravindra,Ganesh ^[8] ; John C,O'Horo ^[1]

作者单位： Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA. ^[1] Division of Community Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. ^[2] Department of Family Medicine, Mayo Clinic Health System-Mankato, Mankato, Minnesota, USA. ^[3] Department of Pharmacy, Mayo Clinic Health System-Eau Claire, Eau Claire, Wisconsin, USA. ^[4] Division of General Internal Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA. ^[5] Division of Infectious Diseases, Mayo Clinic Arizona, Phoenix, Arizona, USA. ^[6] Department of Nursing, Mayo Clinic, Rochester, Minnesota, USA. ^[7] Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. ^[8] Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA. ^[9]

关键词 COVID-19 bebtelovimab hospitalization monoclonal antibodies sotrovimab

DOI 10.1093/ofid/ofac411

PMID 36213724

发布时间 2022-10-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Open forum infectious diseases

2022年9卷10期

ofac411页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.

Open forum infectious diseases

相似文献

Open forum infectious diseases

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.

Open forum infectious diseases

相似文献

Open forum infectious diseases

相关期刊

检索历史清除